HIV/AIDS Unit, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Rome, Italy.
Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global Health, UCL, London, UK.
Nat Commun. 2022 Aug 22;13(1):4922. doi: 10.1038/s41467-022-32263-7.
In order to investigate safety and immunogenicity of SARS-CoV-2 vaccine third dose in people living with HIV (PLWH), we analyze anti-RBD, microneutralization assay and IFN-γ production in 216 PLWH on ART with advanced disease (CD4 count <200 cell/mm and/or previous AIDS) receiving the third dose of a mRNA vaccine (BNT162b2 or mRNA-1273) after a median of 142 days from the second dose. Median age is 54 years, median CD4 nadir 45 cell/mm (20-122), 93% HIV-RNA < 50 c/mL. In 68% of PLWH at least one side-effect, generally mild, is recorded. Humoral response after the third dose was strong and higher than that achieved with the second dose (>2 log difference), especially when a heterologous combination with mRNA-1273 as third shot is used. In contrast, cell-mediated immunity remain stable. Our data support usefulness of third dose in PLWH currently receiving suppressive ART who presented with severe immune dysregulation.
为了研究在接受抗逆转录病毒治疗（ART）且病情较严重（CD4 计数＜200 个/立方毫米和/或既往有艾滋病）的艾滋病毒感染者（PLWH）中接种第三剂 SARS-CoV-2 疫苗的安全性和免疫原性，我们分析了 216 名接受了第三剂 mRNA 疫苗（BNT162b2 或 mRNA-1273）的 PLWH 中的抗 RBD、微量中和试验和 IFN-γ产生情况，他们在第二剂接种后中位数 142 天接受了第三剂疫苗。中位年龄为 54 岁，中位 CD4 计数最低值为 45 个/立方毫米（20-122），93%的 HIV-RNA＜50 c/mL。在 68%的 PLWH 中记录到至少一种副作用，通常为轻度。第三剂接种后的体液免疫反应强烈且高于第二剂（＞2 个对数差异），尤其是使用 mRNA-1273 作为第三剂进行异源组合时。相比之下，细胞介导的免疫保持稳定。我们的数据支持在目前接受抑制性 ART 且存在严重免疫失调的 PLWH 中使用第三剂疫苗。
Zotero 插件
